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Abstract 
The literature contains a number of studies exploring factors impacting on cleaner 
production, but few studying these factors simultaneously. This study has identified these 
factors in the literature and represented their relationships with cleaner production in a 
conceptual framework. The key factors included in this framework are ISO14001 
certification, eco-innovation of product and process, industrial and government regulations, 
and environmentally-friendly culture. Nine major Chinese pharmaceutical companies in 
Tianjin, China, have been used as case study companies to explore the impact of these key 
factors on cleaner production. The analysis reveals that companies that have ISO14001 
certification are likely to be one step ahead; however ISO14001 certification is not the only 
factor leading these manufacturing companies to be active in cleaner production. It is green 
process innovation rather than product innovation that directly impacts on cleaner production. 
The environmentally-friendly culture significantly influences the promotion of cleaner 
production. It is concluded that the industry needs to promote process-oriented innovations 
and build environmentally-friendly culture in order to be more active in cleaner production in 
the long-run. This paper provides case-based insight for cleaner production and 
environmental sustainability researchers and the strategic direction for manufacturing 
companies to achieve cleaner production and environmental sustainability. 
 
Keywords 
Cleaner production, Process innovation, ISO14001, Environmentally-friendly culture 
 
Highlights: 
1. The study explores key factors impacting on cleaner production. 
2. Process innovation impacts cleaner production more profoundly than product innovation. 
3. ISO14001 certified companies are one step ahead in cleaner production. 
4. ISO14001 is not the only way for companies to be active in cleaner production. 
5. An environmentally-friendly culture promotes cleaner production. 
 
The total word count: 11,254 including the title page, acknowledgement, tables and 
appendices. 
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1. Introduction 
Promoting cleaner production in companies is particularly important for improving 
environmental performance within companies, along their supply chains, and to wider 
society. Understanding factors impacting on cleaner production enhances the promotion of 
cleaner production. The cleaner production literature, to some extent, has explored the impact 
of specific factors, including green product and process innovations, use of international 
standards, regulations, and environmentally-friendly culture on the cleaner production. In 
particular, green product innovation contributes to cleaner production in either one or all of 
the following: energy minimisation, material reduction, and pollution prevention (Dangelico 
and Pujari, 2010). Green production process reduces material, energy and water usage and 
generates less waste through the improved process efficiency (Chowdary and George, 2012). 
The use of International Standards Organisations (ISO)’s ISO14001 environmental 
management system (EMS) has impacted positively on manufacturing companies’ 
environmental performance (Vries et al., 2012). Enforcement of industrial and government 
regulations influences companies’ environmental effort (Abreu, 2009; Testa et al., 2012). The 
lack of environmentally-friendly culture creates a barrier for promoting cleaner production in 
organisations (Lober, 1998; Vieira and Amaral, 2016).  
 
This study aims to explore the impact of key factors on cleaner production, at the unit of 
analysis of the firm. Environmentally beneficial or green product and process innovations, 
also termed eco-innovations, the use of ISO14001, industrial and government regulations, 
and environmentally-friendly culture appear to be four key factors impacting on 
manufacturing companies’ cleaner production. Research has been published in exploring the 
impact of one or two of these four key factors on cleaner production (Chowdary and George, 
2012; Dangelico and Pujari, 2010; Lober, 1998; Vries et al., 2012). However, there has been 
no published empirical research which has studied the impact of these factors simultaneously 
on cleaner production and not within the pharmaceutical industry. 
 
Pharmaceutical manufacturers share commonality in terms of production process with some 
other manufacturing companies, from preparing raw ingredients, mixing and filling, and 
finally packaging (Amstead et al., 1987). However, they generate unique wastes in the 
production process, such as solvent water and residue waste at the end of the production 
process. In addition, most drugs, medicines or intermediates contain some chemical 
compounds which are likely to be toxic or polluting to the environment if no actions have 
been taken to degrade those unsold or returned (Fatta-Kassinos et al., 2011). The industry 
presents a substantial opportunity for improving its environmental footprint by considering 
implementing prevention-based approaches, reducing the disposal of residual wastes and 
solvent water, and degrading unused and returned products (Fatta-Kassinos et al., 2011; 
Kreisberg and Zheng, 2011). Therefore, a cleaner production study in this industry is 
particularly relevant to achieving cleaner production and environmental sustainability.  
 
The rapid economic growth in China over the last three decades is coupled with a large 
increase in the overall volume of manufacturing activities. This has caused significantly 
increased pollution in most major cities in China (Yu and Wen, 2010). Effectively reducing 
pollution in major cities is therefore very critical for pollution reduction in China. Therefore, 
we have selected pharmaceutical manufacturing companies in Tianjin, a major city and a 
centre of the pharmaceutical industry for over a century, as our case study companies. Most 
Chinese pharmaceutical manufacturers produce both modern Chinese medicines and western 
medicines, where the manufacturing processes are similar, except for generating a greater 
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amount of residue waste when producing Chinese medicines. The generic process applicable 
to both product streams is described in Figure 1. 
 
 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*. Carbon dioxide (CO2) 
Figure 1. A process map of the pharmaceutical production process and critical control points 
of wastage and pollution (developed from a visit to one Tianjin Chinese pharmaceutical 
manufacturing company in 2012) 
 
The production process generally contains six key production stages, from ‘preparing 
ingredients and mixture’ to ‘labelling and packaging’ (see the six text boxes in Figure 1). 
Along this production process, there are a number of positions which can be controlled by 
companies in terms of wastage and pollution generation and we term these points as critical 
control points (see the numbered items from 1 to 6 in Figure 1). This process map with 
critical control points was developed in this study based on a visit to one of the 
pharmaceutical manufacturers in Tianjin. This process map, which illustrates the production 
process for pharmaceutical manufacturers, is also generic in a way as it shares similarities 
with many types of manufacturing processes (Department of the Environmental-Industrial 
Profile, 1995; Amstead et al., 1987). The map helps to understand cleaner production of 
pharmaceutical manufacturers discussed in this paper. 
 
In order to achieve the research aim, this study proposes a conceptual framework derived 
from the literature (Shields, 1998), and employs a non-linear, multiple stage case research 
model (Stuart et al., 2002). The conceptual framework describes the impact of each of the 
four factors on cleaner production. A comparison is made between the data from the case 
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study organisations and the relationships presented in the conceptual framework which 
facilitates discussions to achieve the research aim. 
 
This paper contributes to the cleaner production literature through exploring key factors 
impacting on cleaner production. In particular, this study improves understanding of the roles 
of ISO14001 certification, eco-innovation of green product and process, the regulatory 
environment, and environmentally-friendly culture impacting on cleaner production. This 
study has used a qualitative, single comparative case study to establish relationships between 
these key factors and cleaner production, which contributes to theory building and 
refinement. This paper explores whether these factors impact on cleaner production and most 
importantly on how and why these factors impact on cleaner production. The findings can be 
used for academic researchers to undertake further research in this study field, for example, to 
make a comparison between different industries or different countries. The findings can also 
be used as a basis to establish hypotheses to be tested using a large survey sample in order to 
quantify the strength of the causal relationships between these factors and cleaner production 
and environmental and firm performance (Li and Hamblin, 2001 and 2003). The findings can 
also be used for companies to understand and improve their cleaner production in order to 
generate more effective strategies and practices to enhance their environmental performance 
results.  
 
The next section reviews the literature and presents the conceptual framework. A non-linear, 
multiple-stage case research model is explained in the methods section, followed by the case 
study company profiles. The data results are presented and discussed by analysing and 
comparing to the literature findings summarised in the conceptual framework. Conclusions 
are drawn and further research areas are proposed at the end. 
 
2 Literature review 
First of all, we clarify the meaning of the concept of cleaner production for this research. 
Cleaner production considers all decisions, activities and actions associated with improving 
environmental performance through reducing negative impact on the environment, not just 
pollution control activities of a production process. This is consistent with the definition by 
Ortolano et al. (1999) which is ‘making efforts to avoid adverse environmental impacts 
throughout a product’s life cycle - from raw material extraction, through product design, 
manufacture, and use and finally to product disposal’ (page 432). In this paper, we focus on 
decisions, activities and actions of reducing negative impacts on environment, specifically 
relating to products and their production processes. 
 
This literature review is organised in five sub-sections. The first four sub-sections review 
ISO14001, eco-innovation of product and process, industrial and government regulations, and 
environmentally-friendly culture and their impacts on cleaner production. The review places 
a particular emphasis on China and the pharmaceutical industry. The last sub-section presents 
the conceptual framework and proposes the research questions. 
 
2.1 ISO14001 certification: benefits and its trend in China 
ISO14001 is a voluntary international standard for developing, establishing, and maintaining 
an effective EMS in organisations worldwide (ISO14001, 2004). Since ISO14000 series were 
introduced in 1996, ISO14001 has been used in many organisations in different industries in 
different countries to develop and maintain their EMSs (ISO survey, 2012). The benefits of 
implementing a certified ISO14001 have been widely recognised. These include: 
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(1) improved market position through a better public image of corporate responsibility, 
(2) increased environmentally sustainable practices,  
(3) improved employee awareness of environmental issues, 
(4) enhanced social sustainability by establishing a better relationship with society, and 
(5) enhanced economic sustainability (Psomas et al., 2011; Searcy et al., 2011).  
 
Implementing the ISO14001 certification has a positive impact on cleaner production and 
also contributes to social sustainability and economic sustainability (Psomas et al., 2011; 
Searcy et al., 2011). These benefits explain the increase of the number of firms being 
ISO14001 certified at a virtually exponential rate in China over the last decade (see Figure 2).  
 
 
 
 
Figure 2. The number of companies certified with ISO14001 in China from 1996 to 2012 
(Raw data extracted from ISO survey, 2012) 
 
Even in the early years of implementation of ISO14001 in China, firms with certified EMS 
had managed their environmentally-based daily activities much more effectively, and had a 
positive impact on environmental performance (Matouq, 2000). Implementing voluntary 
international standards can be very costly to firms (Vastag and Melnyk, 2002). Benefits must 
be greater than costs to result in an increased number of firms gaining and maintaining 
ISO14001 certification globally. Based on a large Chinese company database over a five-year 
period, a study confirmed that ISO14000 certification has significantly contributed to the 
firm’s profitability (Yang and Yao, 2012). 
 
Overall, the certification of ISO14001 in China has dramatically increased over the recent 
decades. However, the number of companies with ISO14001 certification is still limited 
compared to the total population due to limited human and financial resources available in a 
developing country (Massoud et al., 2010). Nevertheless, the benefits of being certified ISO 
14001 are clearly recognised in the literature.  
 
2.2 Eco-innovation and cleaner production 
Eco-innovation includes many types of innovation which explicitly emphasise the reduction 
of environmental impact, ranging from innovations in products, processes, marketing and 
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organisational methods to social and institutional structures (Kesidou and Demirel, 2012). 
Developing green products contributes to reduction of materials and energy usage and 
pollution prevention along a product life cycle (Dangelico and Pujari, 2010). Products have 
their development, production, consumption and disposal life cycle. Eco-innovation 
improvement at any stage of this life cycle contributes to cleaner production. This research 
focuses on product development and production stages. As far as product development is 
concerned, eco-innovation refers to new or improved product designs with conscious 
consideration of using eco-friendly materials and increased possibilities for recycling and 
reuse at the end of product life cycle (Romli et al., 2015). For production processes, eco-
innovation refers to conscious consideration of improving eco-efficiency of a production 
process (Dencic, et al., 2014). An improved eco-efficiency production process reduces the 
use of materials, energy and water, leading to less wastage and pollution, which can be 
achieved through improved production planning approaches and use of technology (Dencic, 
et al., 2014; Grundemann, et al., 2009). Different companies may have different designs of 
products and produce their products using different processes and technologies, which result 
in different environmental performance in terms of material, energy and water usage and 
waste and pollution generation (Ekins, 2010). Both green products and processes are relevant 
to pharmaceutical manufacturing companies, through developing new medicines and 
investing in green technologies for production processes. 
 
Eco-innovations can be either ‘end-of-pipeline’ approaches or process-oriented ‘integrated’ 
methods, or some in between (Van Hoek, 1999). Most ‘end-of-pipeline’ approaches are 
reactive and are pollution control-oriented. Process-oriented ‘integrated’ methods are 
preventive in nature and reduce amount of waste generated in the first place (Lober, 1998). 
Hence, process-oriented preventive approaches are more effective than ‘end-of-pipeline’ 
approaches in terms of longer term environmental performance improvement of a company 
and along its supply chain (Lee and Rhee, 2005).  
 
As far as China is concerned, green process innovation has been explored in terms of its 
contribution to cleaner production in Chinese firms. For example, green production process 
innovation has been made in the coal-fired electricity industry in China (Yu et al., 2011). 
Their study concluded that eco-innovation led to a more efficient production process and was 
the determinant in decreasing resource use and environmental impact (Yu et al., 2011). There 
are industry level studies directly exploring eco-innovations in the pharmaceutical industry in 
China (Hu and Phillips, 2011; Suthar and Singh, 2012). The use of bio-fuel has contributed to 
Chinese pharmaceutical companies’ cleaner production significantly since 2000 (Hu and 
Phillips, 2011). The developed phytotoxicity screening method composted herbal 
pharmaceutical industry waste to be used in the crop production (Suthar and Singh, 2012). 
 
However, Altenburg et al. (2007) found that mounting innovation efforts only rarely 
materialised in cutting-edge innovations in China but suggested that if capital accumulation 
proceeded at the current pace, innovation capabilities would rapidly be built up in China 
(Wang et al., 2010). With the increased awareness of environmental issues in China, these 
innovation capabilities will certainly enhance eco-innovation and have a positive impact on 
future cleaner production in China (Wang et al., 2010). 
 
2.3 Environmental related regulations for the Chinese pharmaceutical companies 
The pharmaceutical industry has long been and still is one of the most extensively regulated 
industries amongst all (Vogel, 1998). Each country has their own regulations regarding drug 
development and production. China established the State Drug Administration (SDA) in 
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1998, which was renamed the State Food and Drug Administration (SFDA) in 2003. SDA 
issued the Good Manufacturing Practices (GMP) regulations in 1999. GMP is an 
international standard for production and testing practices that help to ensure quality 
products. Many countries have legislated pharmaceutical and medical device companies to 
follow GMP procedures, and these countries have created their own GMP guidelines. China’s 
Drug Administration Law states that all pharmaceutical manufacturers must meet and follow 
the national GMP standards. When applying the national GMP certification in China, a 
description of the air-cleaning system and water systems, and an environmental production 
certificate, are required, besides other documents (Liang, 2006). Therefore, the China’s 
national GMP requires Chinese pharmaceutical manufacturers to reach a certain standard in 
cleaner production, represented in the requirements of air-cleaning systems, water systems 
and production processes.  
 
The cleaner production strategy (the CP strategy) has become a key strategy in Chinese 
policy development since the United Nations Conference on environment and development 
took place in 1992 (Wang, 1999). ‘The CP strategy’ in China includes a new policy 
framework for industrial development and environmental protection (Wang, 1999). A 
significant number of Chinese enterprises have adopted ‘the CP strategy’ to measure and 
improve their production processes and have achieved substantial reductions in pollution. 
However, it was only a starting point of a long journey of pollution prevention and reduction 
in China at that time. Many barriers, such as knowledge and awareness, regulatory 
impediments, financial resources, technological hurdles and organisational barriers were 
identified for that time period (Wang, 1999). The enforcement of regulations has been made 
since then. For the pharmaceutical industry, this includes the implementation of the 
compulsory national GMP standards into practice in 2003; the issue of the current GMP 
(cGMP) which is a European standard but not compulsory in 2010; and the promotion of 
ISO14000 series from 2012 to the present day. 
 
The Chinese government has adopted the principle of a ‘circular economy’ and has used 
strategic environmental assessment (SEA) as a tool to reinforce governmental policy 
development (Hong and Li, 2013; Ren et al., 2010). ‘Circular economy’ is a generic term for 
the reducing, reusing, and recycling activities conducted in the process of circulation, 
consumption, and production (Hong and Li, 2013, page 129). The policy switches ‘fast and 
well’ to ‘well and fast’ economic development (Ren et al., 2010). Even though there is still a 
long way to go, an awareness of environmental issues by companies has been dramatically 
enhanced over the last few years in China, with the enforcement of industrial government 
regulations and policies (Hong and Li, 2013; Ren et al., 2010). 
 
2.4 Environmentally-friendly culture and cleaner production 
The management literature indicates that the organisational culture impacts on the adoption 
of management approaches in companies (Stirzaker, et al, 2011). Organisational culture 
contains multiple dimensions, including communication between employees and 
management teams, employee participation, management commitment, and strategic 
importance of organisational goals (Ginevičius and Vaitkūnaite, 2006).  
 
Pollution prevention, particularly in relation to its strategic importance to companies, has 
long been recognised as an important dimension of organisational culture and an opportunity 
for entrepreneurship (Deltas et al, 2014; Lober, 1998). The development of an 
environmentally-friendly culture needs to be supported at the corporate and strategic level in 
order for any cleaner production initiatives to be successful (Stone, 2000). 
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Environmentally-friendly culture makes a positive impact on environmental quality through 
conscious engagement in reducing the level of consumption and enhancing the consideration 
of sustainability (Schumacher, 2015). Environmentally-friendly culture is more likely to 
impact positively on the companies’ environmental performance and contributes to 
companies’ operational and marketing performance (Fraj et al, 2011). The lack of the 
environmentally-friendly culture creates barriers for an organisation’s commitment to cleaner 
production (Lober, 1998; Vieira and Amaral, 2016). 
 
Organisational culture, particularly environmentally-friendly culture, is complex and multi-
dimensional. As far as this research is concerned, the environmentally-friendly culture is 
characterised by a company’s outlook towards its role of being ethical to the environment and 
practising good citizenship (Ajami, 2007; Thomas, 2002) as well as taking cleaner production 
and environmental sustainability as strategically important to the company’s business 
development (Lober, 1998). 
 
2.5 The conceptual framework and research questions 
The literature clearly supports the positive impact of the use of ISO1400, eco-innovation of 
product and process, industrial and government regulations, and environmentally-friendly 
culture on manufacturing companies’ cleaner production. Therefore, we embrace these 
literature findings into a conceptual framework. 
 
Our conceptual framework contains four propositions which summarise the relationships 
between the four key factors and cleaner production, derived from the literature (Figure 3). 
This conceptual framework is used to represent the four propositions in an overall framework 
to be compared with experiences of the case study organisations. Recognition of variations 
between practices of empirical case companies and relationships represented in the 
conceptual framework aids understanding of the underlying reasons and supports 
recommendations for organisations in practice. According to Shields (1998), the use of the 
conceptual framework increases the reliability and validity of the data analysis through the 
systematic comparison of practice to existing theories.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The conceptual framework of the four propositions derived from the literature 
Cleaner 
production  
1. The use of ISO14001 positively impacts on manufacturing 
companies’ environmental performance (Psomas et al., 2011; 
Yang and Yao, 2012).  
 
2. Eco–innovation, particularly green product and process 
innovations, positively impacts on waste/pollution reduction 
and energy usage (Dangelico and Pujari, 2010).  
 
3. Enforcement and promotion of GMP, cGMP, ‘the CP strategy’ 
enforce pharmaceutical companies to pursue their cleaner 
production (Hong and Li, 2013; Wang, 1999). 
4. Developing an environmentally-friendly culture reduces 
barriers for organisations in developing and implementing 
cleaner production (Lober, 1998; Stone, 2000; Vieira and 
Amaral, 2016). 
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In order to explore these propositions, we put forward the following research questions to 
explore ‘why’ and ‘how’ each of these four key factors has impacted on cleaner production: 
 
1. How does the international standard of ISO14001 impact on cleaner production? 
2. Which type of innovation, product or process or both, contributes more profoundly to 
cleaner production and why? 
3. How do the industrial and government regulations shape cleaner production? 
4. How does the environmentally-friendly culture make a difference in cleaner production? 
 
The next section presents methods used for the investigation of these research questions in 
order to achieve the research aim of the exploration of factors impacting on cleaner 
production. 
 
3. Methods 
A non-linear five-stage case research process model is developed for this research (see Figure 
4). It is based on the five-stage case research process model proposed by Stuart et al. (2002, 
page 420) for conducting Operations Management research. The non-linear feature is 
frequently presented in case research studies in Operations Management research (Seuring, 
2008). This provides continuous improvement opportunities for the work conducted at early 
stages. The repetition of stages ensures the rigor of the case research method in practice and 
allows the theoretical constructs to form in order to achieve the research aim more profoundly 
(Seuring, 2008). This non-linear approach for case study research also improves the 
reliability of the research process and validity of the research findings because of continuous 
improvement of research stages until the final conclusions can be drawn. The case research 
process for this study is explained below. 
 
 
 
 
 
 
 
 
Figure 4. The non-linear five-stage case research process model (developed from Stuart et al., 
2002, page 420) 
 
Stage 1-define the purpose of the research, (re)define research question(s), and propose the 
conceptual framework from the literature 
The general purpose of a research can be theory building, theory testing, theory refinement or 
a combination of any two or three of these (Meredith, 1998; Voss et al., 2002). A case study 
method is a primary method to theory building in the Operations Management field 
(Meredith, 1998; Stuart et al., 2002) and used widely for theory refinement (Meredith, 1998). 
We consider that our research fits into theory building and has some elements of theory 
refinement; however it is not for theory testing (Seuring, 2008; Voss, et. al., 2002). This is 
because some studies explored the factors of eco-innovation, ISO14001, industrial and 
government regulations, and environmentally-friendly culture individually rather than 
collectively in the context of China (Hu and Phillips, 2011; Qi et al., 2011; Suthar and Singh, 
2012; Wang, 1999; Wang et al., 2010; Zeng et al., 2005). This research intends to explore 
these factors simultaneously and explore ‘why’ and ‘how’ questions regarding these factors, 
Stage 1 
Define research 
question(s)/propose a 
conceptual framework 
Stage 2 
Select case 
companies 
Stage 3 
Gather 
data 
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Present/analyse data by 
comparing to the 
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Draw 
conclusions 
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not just simple ‘what’ questions. Therefore, case research is an appropriate research method 
for this study. 
 
The conceptual framework embracing the key factors and their impact on the matter 
concerned is developed at this stage. The conceptual framework contains propositions to be 
investigated, supporting the generation of the research questions. 
 
Stage 2-select case studies 
The decision of conducting this research in Tianjin was made because Tianjin is a well-
developed city in China, where good cleaner production practices can be easily captured for 
the research purpose. It is also because of its accessibility to a number of manufacturing 
companies. There are 22 major pharmaceutical manufacturing companies in Tianjin. Nine of 
these 22 companies returned questionnaires within one month and were willing to answer 
further questions if needed. For confidentiality, the companies are coded A to I. The company 
profiles are given in the next section. 
 
We can claim our sampling method as a ‘convenience sampling’ method (Voss et al., 2002). 
This sample contains 41 per cent of the total population of the major pharmaceutical 
manufacturing companies in Tianjin. We aimed to include some companies which are 
ISO14001 certified. We also aimed to include some companies which have been involved in 
cleaner production decisions, activities and actions in the past few years. Five companies in 
these nine are ISO14001 certified. Seven out of these nine companies have implemented 
some cleaner production decisions, activities and actions over the last five years. Therefore, 
both criteria for sampling, which are the ISO14001 certification and involvement in cleaner 
production decisions, activities and actions, have been satisfied. 
 
Stage 3-design questionnaire and gather data 
We employed a questionnaire approach for our data collection. Two questionnaires were 
used. The first one collected general information of the companies (Appendix 1), which 
contributed to the characterisation of the company profiles for this study. Additional 
information from other documentation regarding companies was also collected to complete 
the company profiles. The second questionnaire specifically investigated an individual 
company’s cleaner production decisions, activities and actions using six open-ended 
questions (Appendix 2).  
 
In the second questionnaire, the first question is concerned with the usage of an EMS, which 
targets the first research question regarding ISO14001 EMS and equivalent systems used. 
Question 2 investigates the decisions, activities and actions implemented over the last 5 years 
for improving the production process towards cleaner and greener production. Question 3 
explores specific technologies or processes employed in companies in order to respond to the 
environmental regulations, legislation, and policies. Question 4 investigates the difference in 
the production process between producing new and old products in terms of the level of 
‘cleaner production’. Questions 2 to 4 aim to explore the second research question, regarding 
product and process innovations. Question 5 is specifically concerned with the industrial and 
government regulations for the pharmaceutical industry, and is associated with the third 
research question. Question 6 explores the outlook of environmentally-friendly culture by 
companies through investigating the perceived strategic importance of achieving good global 
citizenship and the most important considerations for their businesses. Question 6 serves to 
investigate the fourth research question.  
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One company visit was made prior to design of this research and questionnaire. A working 
relationship has been established with a local experienced researcher, who works in a 
biotechnological institute in Tianjin. The local researcher works as a coordinator with 
industries and therefore has external working relationships with these pharmaceutical 
manufacturing companies and acted as the local link for data collection. Discussions of 
required data and standards were held prior to the data collection to ensure the quality and 
reliability of the data collected. Continual contact with the local researcher has been 
maintained throughout and after the data collection. Other communications have also been 
made to collect additional information, whenever required, to explore ‘why and ‘how’ 
questions in depth. While there are inherent risks in using a third party for data collection, we 
mitigated the risk to a minimum through monitoring the process closely to ensure the 
reliability and validity of the data collected. 
 
Stage 4-present and analysis data by comparing to the conceptual framework 
The data collected for the six questions are presented. We employ the tabulate method to 
present, classify and compare the data amongst companies. The results from the nine 
companies of six questions are classified and synthesised to address the four propositions 
presented in the conceptual framework (Figure 3).  
 
The method used is the guided analysis following the pre-established propositions in a 
developed conceptual framework. The data relating to each of the propositions and the 
corresponding research question are synthesised among these nine companies and comparing 
to the literature findings. The discussions focus on the achievement of the research aim which 
explores factors impacting on the cleaner production. We summarise the relationships 
between the key factors and cleaner production in a graphic format to complete the analysis.  
 
Stage 5-draw conclusions 
Conclusions are drawn based on the findings generated at stage 4. We focus on the four key 
factors identified in the literature and their impact on cleaner production decisions. The 
identified factors which impact on these companies’ cleaner production can be lessons for 
other manufacturing companies. The contributions of this research are specified in the 
conclusions, along with future research opportunities. 
 
4. Case study company profiles 
The case study companies include four private-owned, one joint venture and four state-owned 
enterprises (see Table 1). Two of the state-owned companies have a long history of producing 
Chinese medicines and were private-owned companies prior to 1949. These companies 
produce variety of medicines and the majority produce both Chinese and western medicines. 
Six of them have export business. Table 1 summarises the characteristics of these case study 
companies’ profiles.    
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 Establishment Main products and markets Exporting Other Information 
A 
 
Established in 
1994; private-
owned; 2420 
employees. 
Mainly producing modern Chinese 
medicines in tablets and capsules, and 
some western medicines. Currently the 
largest drop-pills-dosage-form 
manufacturer in China. Targeting the 
cardiovascular and cerebrovascular drug 
market. 
Japan, American 
and some 
European 
countries, besides 
the domestic 
markets. 
A member of the Federation of Chinese 
Medicine Societies in Europe and the EC 
Commissions traditional medicine drug trial 
legislative group. The first to pass the clinical 
drug application by the United States Food and 
Drug Administration (FDA IND) for its 
compound herbal preparations. 
B 
 
Established in 
1996; private-
owned; 495 
employees. 
Mainly producing modern Chinese 
medicines, some western medicines, 
processed raw materials and intermediates, 
and healthcare products. 
For the domestic 
market only. 
Focusing on development in research of 
healthcare related products with a medical 
supplementary function. 
C  
 
Established in 
2004; private-
owned; 230 
employees. 
Producing injections of modern Chinese 
medicines. Focusing on a series of 
cardiovascular and cerebrovascular 
lyophilized powder and water injections 
medicines, and large infusion formulations. 
America, but 
mainly for the 
domestic market. 
Having developed and using advanced 
production technologies and the latest packaging 
technology in its production of these injection 
forms of modern Chinese medicines in the 
industry. 
D  
 
Established in 
2001; private-
owned; 501 
employees. 
Producing biologics and different influenza 
vaccinations. 
For the domestic 
market only. 
Having their own research and development 
centres as well as manufacturing facilities. 
E Established in 
1998; a joint-
venture, 159 
employees in 
Tianjin division. 
Producing bio-medicines in the 
fermentation of Bacillus hyaluronic acid 
(bHA) and pharmaceutical ingredients and 
raw materials for other pharmaceutical 
companies to produce patented medicines. 
Japan, Southeast 
Asia, Korea and 
Australia, besides 
the domestic 
markets. 
A bio-pharmaceutical company and a world 
leader in bio-innovation in the industry. Having 
many factories and research centres across 
China. 
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 Establishment Main products and markets Exporting Other Information 
F 
 
Established in 
1833 as a 
private-owned; 
became state-
owned in early 
50s; 286 
employees. 
Producing modern Chinese medicines in 
liquids, tablets, and granules of 88 
products, ranged from treating colds and 
flues to diabetes and urinary tract 
infections. 
Many Eastern 
countries but also 
New Zealand, 
besides the 
domestic markets. 
Having invested significantly in research on 
Chinese medicine formulations reform 
exploration and technology in 1950s.  Having 
developed its first tablet formulation of 
traditional Chinese medicines (TCM) in 1952. 
G Established in 
1914 as a 
private-owned; 
became state-
owned in early 
50s; 288 
employees. 
Producing modern Chinese medicines in 
eight formulations: ointments, capsules, 
pills, syrups, mixture, wine agents, plaster, 
and liniment, with more than 90 varieties. 
Having eight unique patent varieties and 
four state-protected products. 
America, 
Indonesia, Africa, 
and Malaysia, 
besides the 
domestic markets. 
Australia and Bavaria GMP certification in 1994 
and 1996. The first in Tianjin to pass the ‘the 
most purification’ certificate of Germany and 
Australia GMP standard.  
H Established in 
1992; state-
owned majority 
share; Israeli 
shareholder; 156 
employees. 
Specialised in developing and 
manufacturing anti-viral and anti-tumour 
drugs. Producing the key product of the 
second generation of genetically 
engineered interferon α-2b. 
Europe, America, 
Africa and other 
Asian countries, 
besides the 
domestic market. 
Investing in the international standard production 
lines.  
I Established in 
2007; state-
owned; 57 
employees. 
Producing more than 30 plant extracts and 
also finished products in tablets, capsules 
and granules. Providing specialised 
services to other global pharmaceutical, 
food and health manufacturing companies. 
For the domestic 
market only. 
Having international advanced precision 
analytical equipment in use. Focusing on plant 
extracts and pharmaceutical formulations 
research development and production operations. 
Table 1. A summary of profiles of case study companies 
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5. Case study results 
This section presents the data collected by the six questions in the second questionnaire 
regarding companies’ cleaner production related aspects. The responses to these six questions 
have been summarised in Table 2. Some explanations of the data results are provided in this 
section along with validity of the collected data. 
 
The first column in Table 2 summarises the first question regarding the use of an EMS. Five 
companies have the ISO14001 certification and four have not had any EMS in use. There is 
less than four percent of Chinese listed companies which had ISO14001 certified in 2012, 
based on the most recent published data from the World Bank and the ISO survey of China 
(World Bank, 2012; ISO survey, 2012). As ISO14001 is an EMS of voluntary international 
standards, only a small percentage of companies in developing countries have the resources 
to pursue it (Kim, 2013). Our sample contains a significant percentage of companies which 
are ISO14001 certified, as we aim to explore ISO14001 and other factors impacting on 
cleaner production decisions. Including a high number of ISO14001 certified companies 
increased the validity of research findings through increased relevance to the factor explored. 
 
We consider results from questions 2 and 3 together. Question 2 requires the company to 
provide cleaner production decisions, activities or actions taken over the past five years and 
Question 3 asks specific processes or technologies employed by the company to achieve 
cleaner production targets. The five ISO14001 certified companies have taken at least one 
cleaner production decisions, activity or actions and have invested in updating specific 
processes or technologies in recent years (details see Table 2). Two of the four non-
ISO14001 certified companies, companies F and G, have also implemented cleaner 
production decisions, activities or actions. However, companies H and I, neither being 
certified by ISO14001 nor employing an equivalent EMS, answered ‘no’ to both questions 2 
and 3. Specific cleaner production decisions, activities or actions by these companies are 
normally unique to each of these companies. However, the general principle is the same as 
reducing waste at the final disposal stage and reducing water and energy consumption in the 
production process through improving the process efficiency. These decisions, activities or 
actions can certainly be shared among pharmaceutical manufacturing companies, particularly 
for those which have established conditions to be actively engaged in cleaner production. The 
companies which are not actively engaged in cleaner production certainly need to find a way 
to become engaged first before considering taking any of these cleaner production decisions, 
activities or actions to be successfully implementing them. 
 
Question 4 explores whether the companies produce new products greener and cleaner. This 
includes using less amount of raw ingredients, particularly auxiliary materials for producing 
Chinese medicines, generating less toxic substances, reducing CO2 emissions, or any other 
reduction of negative impact on the environment. Companies A to G all agreed that 
producing new products was greener and cleaner when using improved processes and 
technologies; whereas companies H and I mentioned that no difference was made for 
producing new medicines. Companies D, F and G particularly emphasised that achieving 
cleaner production in producing new products was due to the associated green process 
innovation. Otherwise, no improvement would have been gained towards cleaner production. 
This clearly emphasised the importance of green process innovation to green products 
production and to cleaner production in pharmaceutical manufacturing companies. 
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 Q1 
EMS 
Q2 
Actions/decisions for 
cleaner production 
Q3 
Specific process 
technology for 
cleaner production 
Q4 
Cleaner 
production of new 
products 
Q5 
Industrial 
regulations
/ legislation 
Q6 
Good global citizenship 
and strategic importance 
factors  
A ISO14001 Establishing sewage 
treatment stations to 
perform sewage water 
treatment and recovery, 
and water reuse 
treatments 
Replacing two 
traditional coal-fired 
industrial boilers by 
a three-times more 
efficient modern 
gas-fired boiler 
Yes, and uses the 
improved process 
to produce new 
products 
GMP Yes, and pursue modern 
pharmaceutical 
technology, and export 
performance. 
B ISO14001 Implementing energy 
saving initiatives, both 
for production and 
office operations 
Using improved 
process technology 
for more efficient 
energy consumption 
Yes, along with 
more energy 
efficient process 
GMP Yes, and pursue product 
quality and people 
wellbeing/health. 
C ISO14001 Implementing various 
waste management 
initiatives; establishing 
an odour reduction 
system to reduce the 
unpleasant odour in 
residue waste 
Installing gas 
boilers; renovating 
high energy-
consumption water 
motor pump 
Yes, along with 
more efficient 
boilers and motor 
pumps 
GMP Yes, and pursue product 
quality and modern 
pharmaceutical 
technology. 
D ISO14001 Investing in more 
environmentally 
friendly production 
facilities 
Using more efficient 
production 
technology 
Yes, but only for 
those new products 
using the improved 
production process 
GMP Yes, and pursue product 
quality and modernisation 
of production lines. 
E ISO14001, 
EHS 
system 
Continuously follow 
corporate policy to 
improve cleaner 
production activities 
Some new process 
technology has been 
invested and used. 
Yes, with the 
assistance of new 
technology used in 
production 
GMP and 
cGMP 
Yes, and pursue 
modernisation of 
production lines and 
export performance. 
Continued to the next page 
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Continued from the previous page 
 Q1 
EMS 
Q2 
Actions/decisions for 
cleaner production 
Q3 
Specific process 
technology for 
cleaner production 
Q4 
Cleaner 
production of new 
products 
Q5 
Industrial 
regulations
/legislation 
Q6 
Good global citizenship 
and strategic importance 
factors 
F No Continuous 
improvement in energy 
consumption; 
renovating sewage 
treatment equipment 
Promoting  
powder-pressing 
produced tablets, 
implementing the 
dry-rolled grain 
technology 
Yes, relying on 
production process 
innovation to 
reduce dust and 
improve output 
GMP Yes, and pursue modern 
pharmaceutical 
technology/people’s 
wellbeing/health. 
G No Implementing 
initiatives to improve 
process efficiency 
Implementing more 
efficient production 
technology to 
generate more output 
with less energy 
consumption 
Yes, with process 
innovation for 
producing new 
products 
GMP Yes, and pursue modern 
pharmaceutical technology 
and people’s 
wellbeing/health. 
H No No particular actions 
and decisions taken 
No specific changes 
in process and 
technology 
No difference made GMP and 
cGMP 
Do not know, but consider 
importance of product 
quality/ pharmaceutical 
technology. 
I No No particular actions 
and decisions taken 
No specific changes 
in process and 
technology 
No difference made GMP Think irrelevant, but 
consider importance of 
modernisation of 
production lines/ 
pharmaceutical 
technology. 
Table 2. The summary of responses to the six survey questions collected using the second questionnaire  
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Question 5 is concerned with industrial and government regulations relating to cleaner 
production. The collective information by companies has confirmed the importance of the 
compulsory national GMP for Chinese pharmaceutical manufacturing companies. Only two 
companies amongst these nine have obtained cGMP. In addition, the ‘Pharmaceutical 
Production and Quality Management Practices’ provides practical guidelines consistent with 
GMP to pharmaceutical companies in China for pharmaceutical manufacturing companies to 
follow. Other regulations and relevant laws are the following, which are not listed in Table 2:   ‘Drug Administration Law of the People's Republic of China’  ‘Regulations for the Implementation of the Drug Administration Law of the People's 
Republic of China’  ‘The People's Republic of China-the Chinese Medicine Ordinance’  ‘Prescription drugs and non-prescription drugs category management approach (Trial)’  ‘Drug Quality Control Standards’. 
 
Question 6 investigates whether achieving a good global citizenship is of strategic importance 
to the company and asks the company to specify two strategically important factors to their 
businesses. This question explores the company’s environmental culture. Environmentally-
friendly culture can be reflected by the company’s outlook towards its roles of being ethical 
to environment and society when conducting their business activities (Thomas, 2002). 
Companies A to G all provided positive answers to the question regarding whether good 
global citizenship is of strategic importance to their business. To stress the importance of 
good global citizenship, company G has further emphasised that it adhered to the people-
oriented enterprise development principle to motivate employees to develop their creativity 
and put forward initiatives. The company also advocates ‘enterprise and employee, 
environment and society harmony’. However, companies H and I did not provide positive 
answers to this question. Company H answered ‘not sure’ about this question and company I 
indicated that achieving a good global citizenship had not been given strategic importance 
within the company. In the second part of this question, strategically important factors were 
selected from the following: product quality, produce export, modernisation of production 
lines, modern pharmaceutical technology, western technology, people health, product to 
market, and market share. Modernisation of production lines, pharmaceutical technology, and 
production quality are the most commonly mentioned items as important to these 
pharmaceutical companies. A couple of companies considered export performance and 
people wellbeing and health as the most important to their businesses (see Table 2).  
 
This section summarises the results collected by the six questions regarding cleaner 
production of the nine major Chinese pharmaceutical companies in Tianjin, China. The next 
section analyses these data results by discussing implications and contributions of these 
results to the literature in relation to the four propositions presented in the conceptual 
framework and the four corresponding research questions proposed at the end of the literature 
review section. 
 
6. Analysis and discussions 
The data results support the first proposition of the conceptual framework, which is the 
positive impact of ISO14001 certification on company cleaner production. This is consistent 
with the literature (Matouq, 2000; Psomas et al., 2011). The questionnaire results clearly 
indicate that the companies having the ISO14001 certification are more likely to be one step 
ahead in actively pursuing cleaner production. Further communications with ISO14001 
certified companies confirmed that by pursuing an EMS at the international standard, they 
became more proactive to develop and implement cleaner production initiatives which lead to 
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cleaner production decisions, activities and actions. These ISO14001 certified companies also 
asserted that being certified of ISO14001, they have systematically developed EMSs in place 
and made the company consider reducing wastage, pollution, and improving efficiency in the 
production process of strategic importance to the business. 
 
However, not all non-ISO14001 companies have done less in terms of cleaner production, 
such as companies F and G which were particularly advanced in implementing eco-process 
innovation related cleaner production decisions, activities or actions. This indicates that 
ISO14001 certification is not a sole determining factor to a company’s pursuit of cleaner 
production. This also proposes a question of what drives the non-ISO14001 certified 
companies to pursue cleaner production, which is discussed later in this section. Exploring 
the first proposition addresses the first research question regarding how ISO14001 impacts on 
cleaner production. It is clear that ISO14001 certification empowers the company by 
proactively engaging and strategically recognising the importance of cleaner production to 
the company. 
 
The second proposition in the conceptual framework addresses the positive impact of eco-
innovations of product and process on cleaner production. This proposition is partially 
supported by the data results. The data results confirm that green process innovation has a 
positive impact on cleaner production decision (Dencic, et al., 2014; Ekins, 2010; 
Grundemann, et al., 2009). However, green product innovation alone does not always lead to 
effective improvement in cleaner production, if it does not go along with green process 
innovation. This does not support the general finding on green product innovation as the most 
important factor in achieving cleaner production by Dangelico and Pujari (2010). Our study 
reveals that process innovation drives cleaner production by improving process efficiency 
through green technology. Producing new or greener products without improved processes 
would make little difference in achieving cleaner production. Green product innovation needs 
to go hand-in-hand with green process innovation to be effective in cleaner production. This 
might be unique to the pharmaceutical industry because its products, which are drugs and 
medicines, cannot be readily altered except by formulating with less chemical and toxic 
ingredients (Fatta-Kassinos et al., 2011). However, the production process can be more 
dramatically modified, such as using dry-grain technology instead of the process technology 
which requires a large amount of water in production. It is evidenced by these case study 
companies that green process innovation impacts on cleaner production more profoundly than 
green product innovation. Whether it is unique to the pharmaceutical industry can be 
explored further by researching green innovation of process and product across different 
industries. The current findings on green process and product innovation address the second 
research question regarding the type of innovation impacting on cleaner production more 
profoundly and why. It is clear that in the pharmaceutical industry, green process innovation 
influences the usage of materials, water and energy in producing drugs and medicines more 
significantly than green product innovation.  
 
The importance of green process innovation leads to further discussions regarding approaches 
along the six critical control points illustrated in the process map (Figure 1). Cleaner 
production decisions, activities and actions associated with critical control points of 1 to 3 at 
the early stages of the process are ‘integrated’ process-oriented approaches for cleaner 
production (Van Hoek, 1999). These decisions, activities and actions have reduced the 
wastage of water and the consumption of energy in the first place. The innovations, such as 
using the dry-rolled grain technology and using non-coal fired boilers have dramatically 
improved the process efficiency. This has resulted in less energy, water, and amount of 
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auxiliary materials needed in the first place. The approaches which reduce waste generated at 
the control points 4 to 6 are characterised as ‘end-of-pipeline’ pollution control innovations 
(Van Hoek, 1999). These include sewage water treatment, water reuse treatment, and odour 
reduction treatment. These cleaner production innovations avoid some of the final wastes 
returning to the environment, by transforming them into re-usable materials or reducing the 
level of air pollution. However they do not reduce the amount of waste generated in the first 
place. The ‘integrated’ process-oriented approaches have a more profound impact on the 
overall environmental performance than ‘end-of-pipeline’ approaches (Lee and Rhee, 2005). 
The process map (Figure 1) can be further used to support the development of cleaner 
production initiatives along these six critical control points, with a particular emphasis on 
‘integrated’ process-oriented approaches associated with the first three critical control points. 
 
The third proposition addresses the impact of the industrial and government regulations on 
cleaner production. The conceptual framework considers the positive impact of industrial and 
government regulations, such as GMP, cGMP and the China’s ‘CP strategy’, on cleaner 
production in Chinese pharmaceutical manufacturing companies. It is clear that the Chinese 
government and the pharmaceutical industry encourage companies to pursue international 
environmental standards of ISO14001 which may have an impact on their engagement of 
cleaner production. The data results indicate that the compulsory national GMP in the 
pharmaceutical industry offers good standards for product quality requirements. However it 
does not distinguish companies in terms of their effort in pursuing cleaner production. There 
are also no differences showing in terms of cleaner production effort for those two companies 
which have also obtained the cGMP. This addresses the third research question on how the 
industrial and government regulations shape cleaner production. The need for regulation is 
undeniable; but this research reveals that regulations alone do not distinguish the cleaner 
production effort among these major pharmaceutical companies in China. 
 
The question here is what inspires non-ISO14001 certified companies to pursue cleaner 
production proactively. What prompted two of these non-ISO14001 certified companies to 
pursue their cleaner production? Proposition four addresses this by relating being active in 
cleaner production to an environmentally-friendly culture. This environmentally-friendly 
culture concerned in this study is particularly in relation to the outlook of ethical 
consideration of environment and strategic importance of good global citizenship of business 
practices. All the companies which are active in pursuing cleaner production have viewed 
good global citizenship of strategic importance to their business. The two companies which 
implemented cleaner production but without ISO14001 certification (Companies F and G) 
have over one hundred years’ history in the pharmaceutical industry. These two companies 
consider people’s wellbeing and health as one of the most important factors to their 
businesses. They promote a sustained, stable, and healthy business development. It is clear 
that if a company has not put environmentally-friendly culture associated outlooks, such as 
being a good global citizen and prioritising people’s wellbeing and health, into a strategically 
important position, it is less likely for any environmental improvement decisions, activities or 
actions to be initialised and implemented. It also indicates that an environmentally-friendly 
culture, which is reflected by ethical consideration of business and importance of people’s 
wellbeing and health to the business, drives a company to pursue its cleaner production. This 
follows the same principle that a culture supporting improvement is critical for companies to 
adopt management approaches (Stirzaker et al, 2011). It is particularly critical when 
resources may have restricted the company achieving ISO14001 certification. This may 
explain the difference in their cleaner production effort and indicate the importance of 
environmentally-friendly culture to cleaner production. This addresses the last research 
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question on how the environmentally-friendly culture makes a difference in cleaner 
production. It is evidenced that the environmentally-friendly culture promotes an ethical 
business environment and the strategic importance of cleaner production in the company. 
  
Hence, we summarise the factors impacting on cleaner production supported by the case 
study organisations in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. A summary of the findings regarding factors impacting on cleaner production 
 
Qualitative case-study research provides good insight into the drivers of cleaner production in 
this specific context and allows related factors to be explored. We have conducted a single 
comparative case study to establish relationships between factors. Further studies can be 
conducted using a large sample to test and quantify these relationships. This research is 
theory building and refinement, and its validity and reliability lies in the quality of data 
collected and logic of comparison and synthesis made for improved understanding. In 
addition, longitudinal research within cases and large sample surveys followed by 
econometric modelling approach, would add further insight into the causal relationships 
between any of these factors and cleaner production, environmental and firm performance (Li 
and Hamblin, 2001 and 2003). However, this is outside the scope of this research. 
 
7. Conclusions 
The environmental sustainability literature asserts the importance of the four factors: the use 
of ISO14001, eco-innovation of product and process, industrial and government regulations, 
and environmentally-friendly culture, to cleaner production for manufacturing companies. 
However, limited studies have explored these factors simultaneously impacting on cleaner 
production. Therefore, we have developed the four propositions associated with each of these 
factors in our conceptual framework and proposed research questions accordingly. A five-
step case study research model has been employed, including defining research questions, 
selecting companies, collecting data, analysing and comparing data to the conceptual 
framework, and drawing conclusions to achieve the research aim. 
 
The companies with an ISO14001 certification are more proactive and one step ahead in 
developing and pursuing cleaner production. This is because they have been systematically 
involved in developing their EMSs and put cleaner production as strategically important in 
practice. Studies in other developing countries also confirm the positive influence of 
ISO14001 on companies (Blackman, 2012; Gavronski et al., 2013; Nee and Wahid, 2010). 
This implies that when the resources are available, pursuing the ISO14001 certification in 
manufacturing companies in developing countries is a way forward to their environmental 
sustainability development to gain competitive advantages. 
 
Cleaner Production 
of major Chinese pharmaceutical manufacturing companies 
Green production 
process innovation  
Green product 
innovations 
Environmentally-
friendly culture 
The use of  
ISO14001 
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We note from the company profiles that not all the ISO14001 certified companies are export 
dominated, and we also note that the public-owned organisations do not have this 
certification. According to the literature, Chinese firms pursuing ISO14001 certifications 
were motivated by export requirements from foreign customers (Qi et al., 2011). In 
particular, seeking ‘entrance to the international market’ was identified as the major driver for 
Chinese firms to obtain an ISO14001 certification (Zeng et al., 2005). The experience of our 
case companies did not confirm that export is one key driver for pursuing ISO14001 
certification. In addition, information in the company profiles confirms that private-owned 
companies are likely to obtain ISO14001 certification. As the factors impacting on pursuing 
ISO14001 certification do not fall into the scope of this paper, we suggest the exploration on 
how these factors impact on the pursuit of ISO14001 certification as future research 
opportunities.  
 
The companies’ experiences indicate that it is green process innovation which directly 
impacts on cleaner production in pharmaceutical manufacturing companies in China, through 
improved process efficiency and the use of green technology. Green product innovations 
alone are not adequate to make significant differences on cleaner production for these 
pharmaceutical manufacturing companies. Green product innovations need green process 
innovation to make positive impact on the environmental performance. For green process 
innovations, ‘integrated’ process-oriented approaches, which reduce the waste and pollutant 
emissions generated in the first place, are particularly crucial for achieving profound effects 
in reduction of raw materials usage, and energy and water consumption. ‘End-of-pipeline’ 
green process innovations, which treat generated waste, have a complementary role to 
‘integrated’ process-oriented approaches in pursuing cleaner production. Understanding the 
process and the critical control points using the process mapping tool helps to generate 
innovative ideas to improving cleaner production. The industry needs to promote ‘integrated’ 
cleaner production innovations in order to achieve better environmental performance in the 
long-run. 
 
It is important to conclude that it is an environmentally-friendly culture which makes the 
difference in terms of the companies’ cleaner production, besides ISO14001 certification. If 
the culture does not support ethical consideration of environment and society, it is unlikely 
that the company promotes cleaner production to improve their environmental performance. 
A pharmaceutical company which has a long history appears to inherit its traditional ethical 
value of good citizenship and contribute to the society and environment with harmony. This 
encourages the company to proactively pursue cleaner production. Future research can 
explore which culture dimensions (Ginevičius and Vaitkūnaite, 2006) constitute the 
environmentally-friendly culture and how such culture dimensions can be developed. The 
importance of developing an environmentally-friendly culture is particularly useful for those 
recently established companies which are not yet ISO14001 certified. 
 
This research also reveals that while industrial and government regulations such as GMP and 
‘the CP strategy’ are essential to ensure that the industry maintains threshold production 
quality standards, such regulations do not mandate companies’ cleaner production efforts. 
Future studies can be considered on what are included in the current environmental 
regulations and what else should be developed in these regulations to influence the 
company’s effort in pursuing cleaner production. This can lead to constructive suggestions on 
how to develop the current regulatory framework further to encourage companies to 
proactively engage in development of cleaner production. This will influence policy makers 
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when setting and updating industrial and government regulations to raise the current 
thresholds in order to have a more profound environmental impact in future. 
 
This research contributes to the literature of the cleaner production and environmental 
sustainability in general, through theory building and refinement. In particular, it improves 
the understanding of factors impacting on cleaner production. The findings on the essential 
position of green process innovation clarify some differences presented in the literature and 
also propose some questions for further exploration. The identified factors impacting on 
cleaner production propose the further research areas associated with these factors across 
other industries and different countries. Further research can be conducted to establish 
whether the conclusions of the relationships between these factors and cleaner production can 
be generalised elsewhere in China, other industries, or in other developing countries. Further 
research can also be made to compare these relationships in developing and developed 
countries. Econometrical modelling using large quantitative surveys can be conducted to 
evaluate causal relationships and effect sizes of these factors on cleaner production 
performance, or action research to explore the changes over time in the pharmaceutical 
industry or different industries and countries. 
 
It would also be interesting to explore the inter-relationships between eco-innovation of 
product and process, ISO14001 certification, and environmentally-friendly culture and how 
cleaner production impacts on the environmental and business performance.  However, 
studying the inter-relationships between these factors and relationships between cleaner 
production and environmental and business performance are outside the scope of this 
research. Further studies can explore the inter-relationships among these factors and 
relationships between cleaner production and environmental and business performance to 
address these dimensions for further enhanced cleaner production and environmental 
sustainability development. 
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Appendix 1: Questions for producing company profiles 
1. Company name 
2. Company ownership 
3. Establishment year 
4. The number of employees 
5. Whether export and countries of exporting, if yes 
6. Product range 
7. Product types: traditional Chinese medicines (TCM), Modern Chinese Medicines, 
Western medicine, processed pharmaceutical raw materials, and/or intermediates 
8. GMP and cGMP certification, yes or no, which year 
9. ISO9000 and ISO14000 certification, yes or no, which year 
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Appendix 2: Survey questions, used for this paper, for cleaner production related aspects of 
pharmaceutical companies in Tianjin, China 
1. Does your company have an environmental management system in use? If yes, please 
specify it. 
2. What has your company implemented in the past five years in relation to cleaner 
production (environmental sustainability development)?  
3. What specific technologies or processes has your company employed in order to achieve 
cleaner production (environmental sustainability) requirements or targets set in the 
government policies/regulations? 
4. In comparison to producing old products, is producing new products greener and cleaner, 
such as, using less raw ingredients, particularly auxiliary materials for producing Chinese 
medicines, generating less toxic substances, reducing carbon dioxide emissions, or any 
other reduction of negative impacts on the environment? 
5. Please specify the industrial and government regulations/policies which are directly 
relevant to your company. 
6. Is achieving a good global citizenship relevant to your company’s strategic planning? In 
addition, please select two most important aspects to your company from the following: 
product quality, product export, modernisation of production lines, modern 
pharmaceutical technology, western technology, people health, products to market, 
market share, or others, please specify. 
